Furthermore, evidence for cancer therapy by inhibition of alternative checkpoints such as T cell and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3) and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is emerging (8). This evidence concerns the gene LAG3 and cancer.